CN107532156A - 半胱氨酸蛋白酶 - Google Patents

半胱氨酸蛋白酶 Download PDF

Info

Publication number
CN107532156A
CN107532156A CN201680021601.8A CN201680021601A CN107532156A CN 107532156 A CN107532156 A CN 107532156A CN 201680021601 A CN201680021601 A CN 201680021601A CN 107532156 A CN107532156 A CN 107532156A
Authority
CN
China
Prior art keywords
ides
polypeptide
igg
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680021601.8A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂安·谢尔曼
索菲亚·耶尔努姆
艾玛·努达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Medical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical AB filed Critical Hansa Medical AB
Priority to CN202111557859.9A priority Critical patent/CN114231512B/zh
Publication of CN107532156A publication Critical patent/CN107532156A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
CN201680021601.8A 2015-02-12 2016-02-12 半胱氨酸蛋白酶 Pending CN107532156A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111557859.9A CN114231512B (zh) 2015-02-12 2016-02-12 半胱氨酸蛋白酶

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1502306.2 2015-02-12
GB201502306A GB201502306D0 (en) 2015-02-12 2015-02-12 Protein
PCT/EP2016/053052 WO2016128558A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111557859.9A Division CN114231512B (zh) 2015-02-12 2016-02-12 半胱氨酸蛋白酶

Publications (1)

Publication Number Publication Date
CN107532156A true CN107532156A (zh) 2018-01-02

Family

ID=52781456

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680021601.8A Pending CN107532156A (zh) 2015-02-12 2016-02-12 半胱氨酸蛋白酶
CN202111557859.9A Active CN114231512B (zh) 2015-02-12 2016-02-12 半胱氨酸蛋白酶

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111557859.9A Active CN114231512B (zh) 2015-02-12 2016-02-12 半胱氨酸蛋白酶

Country Status (23)

Country Link
US (5) US10696959B2 (enExample)
EP (2) EP3256580B1 (enExample)
JP (1) JP6961486B2 (enExample)
KR (1) KR102524613B1 (enExample)
CN (2) CN107532156A (enExample)
AU (2) AU2016217800B2 (enExample)
BR (1) BR112017017284A2 (enExample)
CA (1) CA2976003A1 (enExample)
CL (1) CL2017002065A1 (enExample)
CO (1) CO2017009061A2 (enExample)
DK (1) DK3256580T3 (enExample)
EA (1) EA035130B1 (enExample)
ES (1) ES2927234T3 (enExample)
GB (1) GB201502306D0 (enExample)
IL (1) IL253938B (enExample)
LT (1) LT3256580T (enExample)
MX (1) MX390806B (enExample)
MY (1) MY188696A (enExample)
PL (1) PL3256580T3 (enExample)
PT (1) PT3256580T (enExample)
SG (1) SG11201706346QA (enExample)
WO (1) WO2016128558A1 (enExample)
ZA (1) ZA201705113B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021244628A1 (zh) 2020-06-05 2021-12-09 上海宝济药业有限公司 一种酶和病毒的药物组合及其应用
WO2021254479A1 (zh) * 2020-06-18 2021-12-23 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体
CN115998690A (zh) * 2022-11-10 2023-04-25 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
WO2023109928A1 (zh) 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2023116817A1 (zh) * 2021-12-22 2023-06-29 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体的用途

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
JP7425738B2 (ja) 2018-04-03 2024-01-31 ギンコ バイオワークス インコーポレイテッド 眼組織を標的とするウイルスベクター
MX2020010464A (es) 2018-04-03 2021-01-29 Vectores de virus que evitan anticuerpos.
JP7698583B2 (ja) 2019-03-21 2025-06-25 ギンコ バイオワークス インコーポレイテッド 組換えアデノ随伴ウイルスベクター
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
IL292297A (en) 2019-10-17 2022-06-01 Stridebio Inc Adeno-associated viral vectors for treatment of niemann-pick disease type c
EP3931303A1 (en) 2019-12-06 2022-01-05 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
EP4103724A1 (en) 2020-02-14 2022-12-21 Ultragenyx Pharmaceutical Inc. Gene therapy for treating cdkl5 deficiency disorder
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
CA3189878A1 (en) 2020-08-19 2022-02-24 Colin O'BANION Adeno-associated virus vectors for treatment of rett syndrome
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
EP4323015A4 (en) 2021-04-16 2025-10-22 Askbio Inc RATIONALLY POLYPLOID AAV VIRIONS CROSS THE BLOOD-BRAIN BARRIER AND TRIGGER A REDUCED HUMORAL RESPONSE
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
JP2024531138A (ja) 2021-08-11 2024-08-29 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 筋ジストロフィーを処置するための組成物および方法
EP4433587A2 (en) 2021-11-15 2024-09-25 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833B (zh) * 2022-11-08 2024-08-16 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN120677180A (zh) 2022-11-18 2025-09-19 赛斯米克治疗公司 Fc融合分子及其用途
KR20250170709A (ko) 2023-01-06 2025-12-05 사이즈믹 테라퓨틱, 인코포레이티드. 프로테아제 변이체 및 이의 용도
WO2025072144A1 (en) * 2023-09-27 2025-04-03 Osprey Biopharmaceuticals, Inc. Polypeptides having human igg cleavage activity
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009905A1 (en) * 1997-07-02 2007-01-11 Aventis Pasteur Ltd. Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
CN101232900A (zh) * 2005-06-09 2008-07-30 汉莎医药有限公司 IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
CN102026658A (zh) * 2007-12-13 2011-04-20 英特瓦克公司 改进的免疫组合物
CN1756843B (zh) * 2003-03-04 2012-03-21 英特塞尔股份公司 化脓链球菌抗原

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DE60134494D1 (de) 2000-12-21 2008-07-31 Id Biomedical Corp Antigene aus streptococcus pyogenes und zugehörige dna-fragmente
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
NZ536338A (en) * 2002-11-29 2006-04-28 Morinaga Milk Industry Co Ltd Lactoferrin as a cysteine protease inhibitor
ES2380950T3 (es) * 2005-06-09 2012-05-21 Hansa Medical Ab Uso de la proteinasa IdeS ( de S, pyogenes) para tratar enfermedades autoinmunitarias y rechazo de injerto
US7544577B2 (en) * 2005-08-26 2009-06-09 International Business Machines Corporation Mobility enhancement in SiGe heterojunction bipolar transistors
WO2009033670A2 (en) 2007-09-14 2009-03-19 Genovis Ab Method and kits for dissociating fcgamma-receptor-igg complexes and for igg purification and detection
CA2709029A1 (en) 2007-12-21 2009-07-02 Bianca Eser Stability testing of antibodies
WO2010089126A2 (en) 2009-02-09 2010-08-12 Roche Glycart Ag Immunoglobulin glycosylation pattern analysis
EP3135684B1 (en) 2010-05-26 2023-06-28 Intervacc AB Vaccine against streptococcal infections based on recombinant fusion proteins
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
CN103214549B (zh) * 2013-01-15 2015-08-05 珠海市丽珠单抗生物技术有限公司 一种还原免疫球蛋白的方法及其试剂盒
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009905A1 (en) * 1997-07-02 2007-01-11 Aventis Pasteur Ltd. Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
CN1756843B (zh) * 2003-03-04 2012-03-21 英特塞尔股份公司 化脓链球菌抗原
CN101232900A (zh) * 2005-06-09 2008-07-30 汉莎医药有限公司 IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途
CN102026658A (zh) * 2007-12-13 2011-04-20 英特瓦克公司 改进的免疫组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGNISWAMY J等: "Chain A,Igg-degrading Protease", 《GENBANK DATABASE》 *
AGNISWAMY J等: "Crystal Structure of Group A Streptococcus Mac-1:Insight into Dimer-Mediated Specificity for Recognition of Human IgG", 《STRUCTURE》 *
NCBI: "IgG-degrading enzyme/Mac-1 IdeZ[Streptococcus pyogenes]", 《GENBANK DATABASE》 *
赵自叶: "半胱氨酸蛋白酶IdeS的原核表达、纯化、活性鉴定", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021244628A1 (zh) 2020-06-05 2021-12-09 上海宝济药业有限公司 一种酶和病毒的药物组合及其应用
WO2021254479A1 (zh) * 2020-06-18 2021-12-23 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体
WO2023109928A1 (zh) 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2023116817A1 (zh) * 2021-12-22 2023-06-29 上海宝济药业有限公司 一种免疫球蛋白降解酶IdeE的突变体的用途
US12319942B2 (en) 2021-12-22 2025-06-03 Shanghai Bao Pharmaceuticals Co., Ltd. Use of mutant of immunoglobulin degrading enzyme IdeE
CN115998690A (zh) * 2022-11-10 2023-04-25 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Also Published As

Publication number Publication date
US20220170004A1 (en) 2022-06-02
CL2017002065A1 (es) 2018-04-02
US12359183B2 (en) 2025-07-15
WO2016128558A1 (en) 2016-08-18
PL3256580T3 (pl) 2022-11-28
JP6961486B2 (ja) 2021-11-05
AU2016217800A1 (en) 2017-08-10
NZ733959A (en) 2024-07-26
EA035130B1 (ru) 2020-04-30
CA2976003A1 (en) 2016-08-18
GB201502306D0 (en) 2015-04-01
AU2016217800B2 (en) 2021-08-12
US11667905B2 (en) 2023-06-06
LT3256580T (lt) 2022-10-10
MX390806B (es) 2025-03-21
US20180023070A1 (en) 2018-01-25
AU2021266293A1 (en) 2021-12-09
US20250304937A1 (en) 2025-10-02
JP2018506286A (ja) 2018-03-08
US20200283749A1 (en) 2020-09-10
ZA201705113B (en) 2024-01-31
US11214784B2 (en) 2022-01-04
CN114231512B (zh) 2025-02-14
KR102524613B1 (ko) 2023-04-21
US20230357741A1 (en) 2023-11-09
CN114231512A (zh) 2022-03-25
KR20170116137A (ko) 2017-10-18
PT3256580T (pt) 2022-10-03
DK3256580T3 (en) 2022-10-03
SG11201706346QA (en) 2017-09-28
AU2021266293B2 (en) 2024-10-03
CO2017009061A2 (es) 2018-01-16
EP4108768A1 (en) 2022-12-28
ES2927234T3 (es) 2022-11-03
BR112017017284A2 (pt) 2018-04-17
EP3256580A1 (en) 2017-12-20
IL253938A0 (en) 2017-10-31
MY188696A (en) 2021-12-23
US10696959B2 (en) 2020-06-30
EA201791773A1 (ru) 2018-02-28
EP3256580B1 (en) 2022-07-06
MX2017010390A (es) 2017-12-07
IL253938B (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US12359183B2 (en) Cysteine protease
US20230302100A1 (en) Cysteine protease
CN115698279B (zh) 半胱氨酸蛋白酶
HK1240611B (en) Cysteine protease
HK1240611A1 (en) Cysteine protease
HK1240619A1 (en) Cysteine protease
HK1240619B (en) Cysteine protease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Lund, Sweden

Applicant after: Lufthansa biopharmaceutical Co., Ltd

Address before: Lund, Sweden

Applicant before: Lufthansa Pharmaceutical Co., Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180102